Alex A. Adjei

Abstract 1: Mcl-1 downregulation plays a crucial role in the synergistic anticancer activities between PI-3 kinase inhibitors and histone deacetylase inhibitors in primary NSCLC tumorsin vitroandin vivo

Hao Zhang, Elizabeth A. Repasky, Grace K. Dy, 2011 .

Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

Sumithra J. Mandrekar, J. Jett, S. Mandrekar, 2007, Clinical Cancer Research.

K-ras as a Target for Lung Cancer Therapy

A. Adjei, Alex A. Adjei, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MET: a promising anticancer therapeutic target

S. Peters, A. Adjei, Solange Peters, 2012, Nature Reviews Clinical Oncology.

Effective Incorporation of Biomarkers into Phase II Trials

Lisa M. McShane, Sally Hunsberger, L. McShane, 2009, Clinical Cancer Research.

Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials

Sumithra J. Mandrekar, Henry C. Pitot, Daniel J. Sargent, 2011, Clinical Cancer Research.